Skip to main content
Top
Published in: Journal of Community Health 6/2018

01-12-2018 | Original Paper

Assessing Disparities in the Rates of HCV Diagnoses Within American Indian or Alaska Native Populations Served by the U.S. Indian Health Service, 2005–2015

Authors: Brigg Reilley, Jessica Leston, Mona Doshani, Dana L. Haberling, Marissa Person, Thomas Weiser, Melissa Collier, Jonathan Iralu, Jorge Mera, Rick Haverkate

Published in: Journal of Community Health | Issue 6/2018

Login to get access

Abstract

Hepatitis C virus (HCV) disproportionately affects American Indians/Alaska Natives (AI/AN). The Indian Health Service (IHS), via federal and tribal health facilities provides medical services to an estimated 2.2 million AI/AN people in the United States. HCV diagnoses, defined by International Classification of Diseases 9th Revision, Clinical Modification (ICD-9-CM) codes, were analyzed from 2005 to 2015. Results showed 29,803 patients with an HCV diagnosis; 53.4% were among persons born 1945–1965 and overall HCV burden was higher among males than females. These data will help inform local, regional, and national efforts to address, plan for and carry out a national strategy to provide treatment for HCV infected patients and programs to prevent new HCV infections.
Literature
1.
go back to reference Centers for Disease Control and Prevention. (2012). Recommendations for the Identification of chronic hepatitis C virus infection among persons born during 1945–1965. Morbidity and Mortality Weekly Report, 61(RR04), 1–18. Centers for Disease Control and Prevention. (2012). Recommendations for the Identification of chronic hepatitis C virus infection among persons born during 1945–1965. Morbidity and Mortality Weekly Report, 61(RR04), 1–18.
3.
go back to reference Gordon, S., Lamerato, L., Rupp, L., Holmberg, S. D., Moorman, A. C., Spradling, P. R., et al. (2015). Prevalence of cirrhosis in hepatitis C patients in the Chronic Hepatitis Cohort Study (CHECS): A Retrospective and Prospective Observational Study. The American Journal of Gastroenterology, 110, 1169–1177.CrossRef Gordon, S., Lamerato, L., Rupp, L., Holmberg, S. D., Moorman, A. C., Spradling, P. R., et al. (2015). Prevalence of cirrhosis in hepatitis C patients in the Chronic Hepatitis Cohort Study (CHECS): A Retrospective and Prospective Observational Study. The American Journal of Gastroenterology, 110, 1169–1177.CrossRef
4.
go back to reference Ly, K. N., Hughes, E. M., Jiles, R. B., & Holmberg, S. D. (2016). Rising mortality associated with hepatitis C virus in the United States, 2003–2013. Clinical Infectious Diseases, 62(10), 1287–1288.CrossRef Ly, K. N., Hughes, E. M., Jiles, R. B., & Holmberg, S. D. (2016). Rising mortality associated with hepatitis C virus in the United States, 2003–2013. Clinical Infectious Diseases, 62(10), 1287–1288.CrossRef
7.
go back to reference Edlin, B., Eckhardt, B., Shu, M., Holmberg, S. D., & Swan, T. (2016). Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology, 62(5), 1353–1363.CrossRef Edlin, B., Eckhardt, B., Shu, M., Holmberg, S. D., & Swan, T. (2016). Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology, 62(5), 1353–1363.CrossRef
8.
go back to reference Van der Meer, A., Veldt, B., Feld, J., Wedemeyer, H., Dufour, J. F., Lammert, F., et al. (2012). Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA, 308(24), 2584–2593.CrossRef Van der Meer, A., Veldt, B., Feld, J., Wedemeyer, H., Dufour, J. F., Lammert, F., et al. (2012). Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA, 308(24), 2584–2593.CrossRef
9.
go back to reference Bruno, S., Di Marco, V., Iavarone, M., Roffi, L., Crosignani, A., Calvaruso, V., et al. (2016). Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. Journal of Hepatology, 64(6), 1217–1223.CrossRef Bruno, S., Di Marco, V., Iavarone, M., Roffi, L., Crosignani, A., Calvaruso, V., et al. (2016). Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. Journal of Hepatology, 64(6), 1217–1223.CrossRef
11.
go back to reference Reilley, B., Leston, J., Hariri, S., et al. (2016). Birth cohort testing for hepatitis C virus—Indian Health Service 2012–2015. Morbidity and Mortality Weekly Report,, 65, 467–469.CrossRef Reilley, B., Leston, J., Hariri, S., et al. (2016). Birth cohort testing for hepatitis C virus—Indian Health Service 2012–2015. Morbidity and Mortality Weekly Report,, 65, 467–469.CrossRef
12.
go back to reference Ward, J., & Mermin, J. (2015). Simple, effective, but out of reach? Public health implications of HCV drugs. The New England Journal of Medicine, 373, 2678–2680.CrossRef Ward, J., & Mermin, J. (2015). Simple, effective, but out of reach? Public health implications of HCV drugs. The New England Journal of Medicine, 373, 2678–2680.CrossRef
14.
go back to reference Moon, A., Green, P., Berry, K., & Ioannou, G. N. (2017). Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents. Alimentary Pharmacology & Therapeutics, 45(9), 1201–1212.CrossRef Moon, A., Green, P., Berry, K., & Ioannou, G. N. (2017). Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents. Alimentary Pharmacology & Therapeutics, 45(9), 1201–1212.CrossRef
15.
go back to reference McMahon, B. J., Bruden, D., Townshend-Bulson, L., Simons, B., Spradling, P., Livingston, S., et al. (2017). Infection with hepatitis C virus genotype 3 is an independent risk factor for end-stage liver disease, hepatocellular carcinoma, and liver-related death. Clinical Gastroenterology and Hepatology, 15, 431–437.e2.CrossRef McMahon, B. J., Bruden, D., Townshend-Bulson, L., Simons, B., Spradling, P., Livingston, S., et al. (2017). Infection with hepatitis C virus genotype 3 is an independent risk factor for end-stage liver disease, hepatocellular carcinoma, and liver-related death. Clinical Gastroenterology and Hepatology, 15, 431–437.e2.CrossRef
Metadata
Title
Assessing Disparities in the Rates of HCV Diagnoses Within American Indian or Alaska Native Populations Served by the U.S. Indian Health Service, 2005–2015
Authors
Brigg Reilley
Jessica Leston
Mona Doshani
Dana L. Haberling
Marissa Person
Thomas Weiser
Melissa Collier
Jonathan Iralu
Jorge Mera
Rick Haverkate
Publication date
01-12-2018
Publisher
Springer US
Published in
Journal of Community Health / Issue 6/2018
Print ISSN: 0094-5145
Electronic ISSN: 1573-3610
DOI
https://doi.org/10.1007/s10900-018-0528-7

Other articles of this Issue 6/2018

Journal of Community Health 6/2018 Go to the issue